Improved efficacy of intra-aortic balloon pumping by pharmacological myocardial protection for postoperative pump failure after coronary revascularization.
Fifty patients took part in a randomized and prospective study to define the effect of pharmacological myocardial protection when using IABP in patients with postoperative pump failure, following coronary revascularization under cardiopulmonary bypass employing moderate hypothermia and cardioplegia. Pharmacological protection was given to 23 patients, administering coenzyme Q, 5 mg/kg, and aprotinin, 10,000 KIU/kg, intravenously, every 12 hours, following surgery. A single dose of each drug was also given intraoperatively. The postoperative haemodynamics, serum enzyme levels and success of weaning from IABP, were compared between the group of patients who received pharmacological protection (the treated group) and the control group which comprised 27 patients who were treated only with IABP. Among the surviving patients, no significant differences were seen in the hemodynamics or cardiac enzyme levels between the two groups. The rate of successful weaning from IABP however, was 95 per cent in the treated group as compared with only 74 per cent in the control group, p = 0.02. These results suggest that pharmacological myocardial protection, using coenzyme Q and aprotinin in both the intra- and post-operative periods, improves the efficacy of IABP in the treatment of post-operative pump failure following coronary revascularization.
Sunamori
M
M
Department of Thoracic Surgery, Tokyo Medical and Dental University, School of Medicine, Japan.
Suzuki
A
A
D007611:Aprotinin / Q000627:therapeutic use*; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D001026:Coronary Artery Bypass / Q000009:adverse effects*; D006324:Heart Arrest, Induced / Q000009:adverse effects*; D006439:Hemodynamics; D006801:Humans; D007275:Injections, Intravenous; D007423:Intra-Aortic Balloon Pumping; D008875:Middle Aged; D010477:Perfusion; D011184:Postoperative Period; D011446:Prospective Studies; D011897:Random Allocation; D014451:Ubiquinone / Q000627:therapeutic use*
D014451:Ubiquinone; D007611:Aprotinin